China Universal Asset Management Co. Ltd. Buys 2,632 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

China Universal Asset Management Co. Ltd. increased its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 21.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,020 shares of the company’s stock after buying an additional 2,632 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Nurix Therapeutics were worth $283,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of NRIX. Amalgamated Bank lifted its position in Nurix Therapeutics by 30.6% during the 3rd quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after acquiring an additional 511 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Nurix Therapeutics by 31.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock valued at $54,000 after acquiring an additional 559 shares during the period. Quarry LP grew its position in Nurix Therapeutics by 3,746.2% in the 3rd quarter. Quarry LP now owns 2,500 shares of the company’s stock worth $56,000 after purchasing an additional 2,435 shares during the period. International Assets Investment Management LLC increased its position in Nurix Therapeutics by 1,098.4% during the third quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock valued at $101,000 after acquiring an additional 4,119 shares during the last quarter. Finally, Quest Partners LLC boosted its holdings in shares of Nurix Therapeutics by 21.3% in the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock worth $168,000 after buying an additional 1,312 shares during the last quarter.

Insider Activity

In other Nurix Therapeutics news, CFO Houte Hans Van sold 2,811 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $55,798.35. Following the completion of the transaction, the chief financial officer now directly owns 39,549 shares of the company’s stock, valued at approximately $785,047.65. This trade represents a 6.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Gwenn Hansen sold 3,690 shares of the company’s stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the sale, the insider now directly owns 55,937 shares in the company, valued at $1,110,349.45. This trade represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.20% of the company’s stock.

Nurix Therapeutics Stock Down 1.5 %

NASDAQ NRIX opened at $19.71 on Monday. The company has a 50 day moving average price of $20.05 and a 200 day moving average price of $22.36. Nurix Therapeutics, Inc. has a 52 week low of $7.79 and a 52 week high of $29.56. The firm has a market cap of $1.50 billion, a PE ratio of -6.82 and a beta of 2.14.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 63.38%. On average, equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

NRIX has been the topic of several recent research reports. Stephens reaffirmed an “overweight” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research note on Tuesday, January 21st. Royal Bank of Canada increased their price target on Nurix Therapeutics from $26.00 to $27.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Jefferies Financial Group started coverage on shares of Nurix Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $41.00 target price on the stock. Stifel Nicolaus lifted their price objective on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Finally, UBS Group began coverage on Nurix Therapeutics in a research note on Thursday, October 24th. They set a “buy” rating and a $35.00 price target for the company. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, Nurix Therapeutics has an average rating of “Moderate Buy” and an average price target of $30.71.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.